FDA seeks more time to review Takeda's Actos-alogliptin combo

07/23/2009 | Bloomberg

Takeda Pharmaceutical said the FDA moved to Sept. 4 its deadline to decide whether to approve a drug that blends diabetes drugs Actos and alogliptin. Review of the fixed-dose combination is separate from Takeda's application for alogliptin, which failed to gain FDA approval last month.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC